Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

NEW YORK, NEW YORK, UNITED STATES, January 13, 2021 – Manhattan BioSolutions, Inc. (MABS), an emerging biotechnology company focused on the discovery […]

Fort Lee, New Jersey Mar 10, 2022 (Issuewire.com)  – Manhattan BioSolutions, an emerging biotechnology company focused on the development of innovative biologic therapies for […]